Killer anti-idiotypes in the control of fungal infections

W. Magliani, S. Conti, S. Arseni, R. Frazzi, A. Salati, L. Polonelli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Killer anti-idiotypes (KTantiId) bear the internal image of Pichia anomala toxin (KT), characterized by microbicidal activity against prokaryotic and eukaryotic pathogenic microorganisms presenting specific cell wall receptors (KTR). KTantiId produced by idiotypic vaccination with a KT-neutralizing monoclonal antibody confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. KTantiId-like human natural anti-KTR antibodies are produced in natural infections caused by KT-sensitive microorganisms. KTantiId in the monoclonal and recombinant forms show therapeutic activity in experimental vaginal candidiasis and Pneumocystis carinii pneumonia. Human commensal bacteria expressing KTantiId or killer mimotopes synthesized from the sequence of KtantiId, may represent effective tools to combat fungal infections.

Original languageEnglish
Pages (from-to)477-479
Number of pages3
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number4
Publication statusPublished - 2001

Fingerprint

Mycoses
Pneumocystis Pneumonia
Pichia
Candidiasis
Neutralizing Antibodies
Cell Wall
Anti-Idiotypic Antibodies
Vaccination
Theoretical Models
Monoclonal Antibodies
Bacteria
Infection
Therapeutics
Systemic candidiasis

Keywords

  • Anti-idiotypes
  • Candidiasis
  • Killer yeast

ASJC Scopus subject areas

  • Pharmacology

Cite this

Magliani, W., Conti, S., Arseni, S., Frazzi, R., Salati, A., & Polonelli, L. (2001). Killer anti-idiotypes in the control of fungal infections. Current Opinion in Investigational Drugs, 2(4), 477-479.

Killer anti-idiotypes in the control of fungal infections. / Magliani, W.; Conti, S.; Arseni, S.; Frazzi, R.; Salati, A.; Polonelli, L.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 4, 2001, p. 477-479.

Research output: Contribution to journalArticle

Magliani, W, Conti, S, Arseni, S, Frazzi, R, Salati, A & Polonelli, L 2001, 'Killer anti-idiotypes in the control of fungal infections', Current Opinion in Investigational Drugs, vol. 2, no. 4, pp. 477-479.
Magliani W, Conti S, Arseni S, Frazzi R, Salati A, Polonelli L. Killer anti-idiotypes in the control of fungal infections. Current Opinion in Investigational Drugs. 2001;2(4):477-479.
Magliani, W. ; Conti, S. ; Arseni, S. ; Frazzi, R. ; Salati, A. ; Polonelli, L. / Killer anti-idiotypes in the control of fungal infections. In: Current Opinion in Investigational Drugs. 2001 ; Vol. 2, No. 4. pp. 477-479.
@article{29b6005026be40e0a52c97f85d28ac21,
title = "Killer anti-idiotypes in the control of fungal infections",
abstract = "Killer anti-idiotypes (KTantiId) bear the internal image of Pichia anomala toxin (KT), characterized by microbicidal activity against prokaryotic and eukaryotic pathogenic microorganisms presenting specific cell wall receptors (KTR). KTantiId produced by idiotypic vaccination with a KT-neutralizing monoclonal antibody confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. KTantiId-like human natural anti-KTR antibodies are produced in natural infections caused by KT-sensitive microorganisms. KTantiId in the monoclonal and recombinant forms show therapeutic activity in experimental vaginal candidiasis and Pneumocystis carinii pneumonia. Human commensal bacteria expressing KTantiId or killer mimotopes synthesized from the sequence of KtantiId, may represent effective tools to combat fungal infections.",
keywords = "Anti-idiotypes, Candidiasis, Killer yeast",
author = "W. Magliani and S. Conti and S. Arseni and R. Frazzi and A. Salati and L. Polonelli",
year = "2001",
language = "English",
volume = "2",
pages = "477--479",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Killer anti-idiotypes in the control of fungal infections

AU - Magliani, W.

AU - Conti, S.

AU - Arseni, S.

AU - Frazzi, R.

AU - Salati, A.

AU - Polonelli, L.

PY - 2001

Y1 - 2001

N2 - Killer anti-idiotypes (KTantiId) bear the internal image of Pichia anomala toxin (KT), characterized by microbicidal activity against prokaryotic and eukaryotic pathogenic microorganisms presenting specific cell wall receptors (KTR). KTantiId produced by idiotypic vaccination with a KT-neutralizing monoclonal antibody confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. KTantiId-like human natural anti-KTR antibodies are produced in natural infections caused by KT-sensitive microorganisms. KTantiId in the monoclonal and recombinant forms show therapeutic activity in experimental vaginal candidiasis and Pneumocystis carinii pneumonia. Human commensal bacteria expressing KTantiId or killer mimotopes synthesized from the sequence of KtantiId, may represent effective tools to combat fungal infections.

AB - Killer anti-idiotypes (KTantiId) bear the internal image of Pichia anomala toxin (KT), characterized by microbicidal activity against prokaryotic and eukaryotic pathogenic microorganisms presenting specific cell wall receptors (KTR). KTantiId produced by idiotypic vaccination with a KT-neutralizing monoclonal antibody confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. KTantiId-like human natural anti-KTR antibodies are produced in natural infections caused by KT-sensitive microorganisms. KTantiId in the monoclonal and recombinant forms show therapeutic activity in experimental vaginal candidiasis and Pneumocystis carinii pneumonia. Human commensal bacteria expressing KTantiId or killer mimotopes synthesized from the sequence of KtantiId, may represent effective tools to combat fungal infections.

KW - Anti-idiotypes

KW - Candidiasis

KW - Killer yeast

UR - http://www.scopus.com/inward/record.url?scp=0035050103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035050103&partnerID=8YFLogxK

M3 - Article

C2 - 11566002

AN - SCOPUS:0035050103

VL - 2

SP - 477

EP - 479

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 4

ER -